Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boule Diagnostics ABCHIX:BOULS 43 Piotroski F-Score is 6 as of Aug. 28, 2026, which is 20% above its 10-year median of 5.00. GuruFocus rates CHIX:BOULS with a GF Score™ of 43/100 and a GF Value™ of kr51.87. The stock has 2 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Boule Diagnostics AB ranks better than 80.52% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Boule Diagnostics AB has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Boule Diagnostics AB's Piotroski F-Score or its related term are showing as below:
CHIX:BOULs'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 5 Max: 8
Current: 6
During the past 13 years, the highest Piotroski F-Score of Boule Diagnostics AB was 8. The lowest was 2. And the median was 5.
Boule Diagnostics AB (CHIX:BOULs) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Boule Diagnostics AB Piotroski F-Score Related Terms
Boule Diagnostics AB Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BOULS vs ABT, SYK, MDT: Piotroski F-Score Comparison
For the Medical Devices subindustry, Boule Diagnostics AB's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB Piotroski F-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Boule Diagnostics AB's current Net Income (TTM) was -3.8.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Boule Diagnostics AB's return on assets of this year was -0.00816502. Boule Diagnostics AB's return on assets of last year was -0.40117076.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Boule Diagnostics AB's gearing of this year was 0.18053873. Boule Diagnostics AB's gearing of last year was 0.12186439.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Boule Diagnostics AB's current ratio of this year was 1.07063712. Boule Diagnostics AB's current ratio of last year was 1.02347826.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Boule Diagnostics AB's number of shares in issue this year was 42.5. Boule Diagnostics AB's number of shares in issue last year was 47.333.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Boule Diagnostics AB's gross margin of this year was 0.42974848. Boule Diagnostics AB's gross margin of last year was 0.44291529.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Boule Diagnostics AB's asset turnover of this year was 0.9909755. Boule Diagnostics AB's asset turnover of last year was 0.64254577.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
1
+
1
+
1
+
0
+
1
+
1
+
0
+
1
=
6
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Boule Diagnostics AB has an F-score of 6 indicating the company's financial situation is typical for a stable company.
Boule Diagnostics AB (CHIX:BOULS) has a Piotroski F-Score of 6 as of Aug. 28, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Boule Diagnostics AB and its competitors. This is 20% above median its historical median of 5.00. Over the past decade, Boule Diagnostics AB's Piotroski F-Score has ranged from 2.00 to 8.00. According to the industry distribution chart, Boule Diagnostics AB ranks #158 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 19.5%.
Is Boule Diagnostics AB's Piotroski F-Score too high?
Boule Diagnostics AB's current Piotroski F-Score of 6 is 20% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 8.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Boule Diagnostics AB's value of 6 is 20% above this industry median. Based on the distribution chart, Boule Diagnostics AB ranks #158 out of 811 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Boule Diagnostics AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's Piotroski F-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #158 out of 811 companies for Piotroski F-Score. This places Boule Diagnostics AB in the top 20% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Boule Diagnostics AB's value of 6 is 20% above this benchmark. Historically, Boule Diagnostics AB's own Piotroski F-Score has ranged from 2.00 to 8.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Boule Diagnostics AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boule Diagnostics AB's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Boule Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current Piotroski F-Score is 6, which is 20% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (CHIX:BOULS) has a current Piotroski F-Score of 6. The stock's GF Value™ is kr51.87, compared to a current price of kr26.30 — trading 49.3% below its estimated fair value. The current Piotroski F-Score is 6, which is 20% above median its 10-year median of 5.00 and 20% above the Medical Devices & Instruments industry median of 5.00. Boule Diagnostics AB's overall GF Score™ is 43/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Boule Diagnostics AB (CHIX:BOULS), the current Piotroski F-Score is 6 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (CHIX:BOULS) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of kr26.30 is trading 49.3% below its estimated GF Value™ of kr51.87.
Key valuation signals for CHIX:BOULS:
Piotroski F-Score: 6 (20% above median its 10-year median of 5.00)
GF Value™: kr51.87 vs. price of kr26.30 (49.3% below fair value)
Industry Position: 20% above the Medical Devices & Instruments median (#158 of 811)
No single metric tells the full story. See the CHIX:BOULS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
43GF Score
Get the complete analysis for CHIX:BOULS
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BOULS has been successfully added to your 
